Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma.
Saved in:
| Title: | Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma. |
|---|---|
| Authors: | Shui, Lin1 (AUTHOR), Cheng, Ke1 (AUTHOR), Li, Xiaofen1 (AUTHOR), Shui, Pixian2 (AUTHOR), Zhou, Xiaohan1 (AUTHOR), Li, Jian3 (AUTHOR), Yi, Cheng1 (AUTHOR), Cao, Dan1 (AUTHOR) hxcaodan2019@163.com |
| Source: | BMC Cancer. 7/9/2020, Vol. 20 Issue 1, p1-8. 8p. 1 Chart, 1 Graph. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 144473075 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Shui%2C+Lin%22">Shui, Lin</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Cheng%2C+Ke%22">Cheng, Ke</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Li%2C+Xiaofen%22">Li, Xiaofen</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Shui%2C+Pixian%22">Shui, Pixian</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Zhou%2C+Xiaohan%22">Zhou, Xiaohan</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Li%2C+Jian%22">Li, Jian</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Yi%2C+Cheng%22">Yi, Cheng</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Cao%2C+Dan%22">Cao, Dan</searchLink><relatesTo>1</relatesTo> (AUTHOR)<i> hxcaodan2019@163.com</i> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22BMC+Cancer%22">BMC Cancer</searchLink>. 7/9/2020, Vol. 20 Issue 1, p1-8. 8p. 1 Chart, 1 Graph. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=144473075 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1186/s12885-020-07126-3 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 8 StartPage: 1 Titles: – TitleFull: Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Shui, Lin – PersonEntity: Name: NameFull: Cheng, Ke – PersonEntity: Name: NameFull: Li, Xiaofen – PersonEntity: Name: NameFull: Shui, Pixian – PersonEntity: Name: NameFull: Zhou, Xiaohan – PersonEntity: Name: NameFull: Li, Jian – PersonEntity: Name: NameFull: Yi, Cheng – PersonEntity: Name: NameFull: Cao, Dan IsPartOfRelationships: – BibEntity: Dates: – D: 09 M: 07 Text: 7/9/2020 Type: published Y: 2020 Identifiers: – Type: issn-print Value: 14712407 Numbering: – Type: volume Value: 20 – Type: issue Value: 1 Titles: – TitleFull: BMC Cancer Type: main |
| ResultId | 1 |
